guest ::
| Home > Publications database > The Complexity of Malignant Glioma Treatment. > print |
| 001 | 299783 | ||
| 005 | 20250314112220.0 | ||
| 024 | 7 | _ | |a 10.3390/cancers17050879 |2 doi |
| 024 | 7 | _ | |a pmid:40075726 |2 pmid |
| 037 | _ | _ | |a DKFZ-2025-00538 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kampers, Linde F C |0 0000-0002-3479-3593 |b 0 |
| 245 | _ | _ | |a The Complexity of Malignant Glioma Treatment. |
| 260 | _ | _ | |a Basel |c 2025 |b MDPI |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1741876626_2409 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Malignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-like cells, in general, and glioma stem-like cells in particular (GSCs), vascularization and hypoxia, metabolic reprogramming, tumor-promoting inflammation and sustained proliferative signaling. Each hallmark drives malignant glioma development, both individually and through interactions with other hallmarks, in which the TME plays a critical role. To combat the aggressive malignant glioma spatio-temporal heterogeneity driven by TME interactions, and to overcome its therapeutic challenges, a combined treatment strategy including anticancer therapies, repurposed drugs and multimodal immunotherapy should be the aim for future treatment approaches. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a immunotherapy |2 Other |
| 650 | _ | 7 | |a malignant glioma |2 Other |
| 650 | _ | 7 | |a tumor microenvironment |2 Other |
| 700 | 1 | _ | |a Metselaar, Dennis |0 P:(DE-He78)eab13a5d37ded394a30e8cef0c57b906 |b 1 |u dkfz |
| 700 | 1 | _ | |a Vinci, Maria |0 0000-0002-7952-6771 |b 2 |
| 700 | 1 | _ | |a Scirocchi, Fabio |0 0000-0002-6408-2055 |b 3 |
| 700 | 1 | _ | |a Veldhuijzen van Zanten, Sophie |0 0000-0002-3888-0977 |b 4 |
| 700 | 1 | _ | |a Eyrich, Matthias |0 0000-0002-8099-5903 |b 5 |
| 700 | 1 | _ | |a Biassoni, Veronica |0 0000-0003-1486-1736 |b 6 |
| 700 | 1 | _ | |a Hulleman, Esther |0 0000-0001-9256-947X |b 7 |
| 700 | 1 | _ | |a Karremann, Michael |0 0000-0002-9961-4752 |b 8 |
| 700 | 1 | _ | |a Stücker, Wilfried |b 9 |
| 700 | 1 | _ | |a Van Gool, Stefaan W |0 0000-0002-8102-5968 |b 10 |
| 773 | _ | _ | |a 10.3390/cancers17050879 |g Vol. 17, no. 5, p. 879 - |0 PERI:(DE-600)2527080-1 |n 5 |p 879 |t Cancers |v 17 |y 2025 |x 2072-6694 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:299783 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)eab13a5d37ded394a30e8cef0c57b906 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCERS : 2022 |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-14 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-14 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-14 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCERS : 2022 |d 2024-12-14 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|